Antithrombin in sepsis revisited.

about

Clinical review: molecular mechanisms underlying the role of antithrombin in sepsis.Systemic versus localized coagulation activation contributing to organ failure in critically ill patients.Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates

P2860

Q36423261-E8B2A598-32B5-40C8-9E0C-9E1AE46269D8 Q37909137-7027AE9D-D6D8-4F9E-9189-83C542571B51 Q42096335-C0AEEE6F-7FCE-4A1B-9789-43647A9CF8FE

P2860

Antithrombin in sepsis revisited.

Item

http://www.wikidata.org/entity/Q43251273

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Antithrombin in sepsis revisited.

@en

Antithrombin in sepsis revisited.

@nl

type

Item

label

Antithrombin in sepsis revisited.

@en

Antithrombin in sepsis revisited.

@nl

prefLabel

Antithrombin in sepsis revisited.

@en

Antithrombin in sepsis revisited.

@nl

P1476

Antithrombin in sepsis revisited.

@en

P2093

Marcel Levi

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of recombinant human activated protein C for severe sepsis

Substitution of antithrombin III in shock and DIC: a randomized study.

Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation.

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

Bidirectional relation between inflammation and coagulation.

Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients.

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.

Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis.

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies.

Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation.

P2888

cc3819

P304

624-625

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC3819

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-09-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7414439

http://www.w3.org/2001/XMLSchema#string

P698

16356248

http://www.w3.org/2001/XMLSchema#string

P921

sepsis

P932

1414019

http://www.w3.org/2001/XMLSchema#string

Antithrombin in sepsis revisited.

about

P2860

P2860

Antithrombin in sepsis revisited.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P932